Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QPUTN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ab4-AM2 D265C.LALA.H435A
|
|||||
| Synonyms |
Ab4-AM2 D265C.LALA.H435A
Click to Show/Hide
|
|||||
| Organization |
Vor Biopharma Inec.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.6
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Receptor-type tyrosine-protein phosphatase C (PTPRC)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 136 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
| Maximum Observed Concentration (Cmax) | 14.7 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
| Time to Maximum Concentration (Tmax) | 0.083 | hr |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 136 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
| Volume of Distribution (Vd) | 81.8 | mL/kg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 136 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 136 | ug/mL/mg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
| Elimination Half-Life (t1/2) | 7.4 | hr |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
| Clearance (CL) | 7.35 | mL/hr/kg |
The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.
|
[1] |
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.025 nM | Positive CD45,Ab4 expression (CD45,Ab4 +++/++) | ||
| Method Description |
In vitro cell line killing assay - IC50 values
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.066 nM | Positive CD45,Ab4 expression (CD45,Ab4 +++/++) | ||
| Method Description |
In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
|
||||
| In Vitro Model | B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia | REH cells (CD45+) | CVCL_1650 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.066 nM | Negative CD45 expression (CD45-) | ||
| Method Description |
In vitro REH cell line killing assay - IC50 values
|
||||
| In Vitro Model | B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia | REH cells (CD45-) | CVCL_1650 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.2378 nM | Positive CD45,Ab4 expression (CD45,Ab4 +++/++) | ||
| Method Description |
In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SKNO-1 cells | CVCL_2196 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.38 nM | Positive CD45,Ab5 expression (CD45,Ab5 +++/++) | ||
| Method Description |
In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||